These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26808409)

  • 1. In Vitro Evaluation of Inhalable Verapamil-Rifapentine Particles for Tuberculosis Therapy.
    Parumasivam T; Chan JG; Pang A; Quan DH; Triccas JA; Britton WJ; Chan HK
    Mol Pharm; 2016 Mar; 13(3):979-89. PubMed ID: 26808409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro evaluation of novel inhalable dry powders consisting of thioridazine and rifapentine for rapid tuberculosis treatment.
    Parumasivam T; Chan JG; Pang A; Quan DH; Triccas JA; Britton WJ; Chan HK
    Eur J Pharm Biopharm; 2016 Oct; 107():205-14. PubMed ID: 27422209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel inhalable form of rifapentine.
    Chan JG; Duke CC; Ong HX; Chan JC; Tyne AS; Chan HK; Britton WJ; Young PM; Traini D
    J Pharm Sci; 2014 May; 103(5):1411-21. PubMed ID: 24585270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Inhaled Combination Powder Containing Amorphous Colistin and Crystalline Rifapentine with Enhanced Antimicrobial Activities against Planktonic Cells and Biofilm of Pseudomonas aeruginosa for Respiratory Infections.
    Zhou QT; Sun SP; Chan JG; Wang P; Barraud N; Rice SA; Wang J; Li J; Chan HK
    Mol Pharm; 2015 Aug; 12(8):2594-603. PubMed ID: 25423590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifapentine-loaded PLGA microparticles for tuberculosis inhaled therapy: Preparation and in vitro aerosol characterization.
    Parumasivam T; Leung SS; Quan DH; Triccas JA; Britton WJ; Chan HK
    Eur J Pharm Sci; 2016 Jun; 88():1-11. PubMed ID: 27049049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection.
    Chan JG; Tyne AS; Pang A; Chan HK; Young PM; Britton WJ; Duke CC; Traini D
    Pharm Res; 2014 May; 31(5):1239-53. PubMed ID: 24242939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhalation of Respirable Crystalline Rifapentine Particles Induces Pulmonary Inflammation.
    Parumasivam T; Ashhurst AS; Nagalingam G; Britton WJ; Chan HK
    Mol Pharm; 2017 Jan; 14(1):328-335. PubMed ID: 27977216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?
    Alfarisi O; Alghamdi WA; Al-Shaer MH; Dooley KE; Peloquin CA
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1027-1036. PubMed ID: 28803492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.
    Sirgel FA; Fourie PB; Donald PR; Padayatchi N; Rustomjee R; Levin J; Roscigno G; Norman J; McIlleron H; Mitchison DA
    Am J Respir Crit Care Med; 2005 Jul; 172(1):128-35. PubMed ID: 15805182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro study on cross resistance of rifampin and rifapentine for Mycobacterium tuberculosis].
    Duanmu HJ; Liu YH; Jiang GL; Wang SM; Fu YH
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Mar; 28(3):192-4. PubMed ID: 15854417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder.
    Chan JG; Tyne AS; Pang A; McLachlan AJ; Perera V; Chan JC; Britton WJ; Chan HK; Duke CC; Young PM; Traini D
    Int J Antimicrob Agents; 2015 Mar; 45(3):319-23. PubMed ID: 25554469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can studies of the early bactericidal activity of rifapentine tell us how to prevent acquired rifamycin-resistant relapse?
    Wallis RS
    Am J Respir Crit Care Med; 2005 Jul; 172(1):4-5. PubMed ID: 15980108
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex.
    Bemer-Melchior P; Bryskier A; Drugeon HB
    J Antimicrob Chemother; 2000 Oct; 46(4):571-6. PubMed ID: 11020254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intramacrophage Mycobacterium tuberculosis efflux pump gene regulation after rifampicin and verapamil exposure.
    Canezin PH; Caleffi-Ferracioli KR; Scodro RBL; Siqueira VLD; Pavan FR; Barros ILE; Cardoso RF
    J Antimicrob Chemother; 2018 Jul; 73(7):1770-1776. PubMed ID: 29579201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhalable spray-dried formulation of D-LAK antimicrobial peptides targeting tuberculosis.
    Kwok PC; Grabarek A; Chow MY; Lan Y; Li JC; Casettari L; Mason AJ; Lam JK
    Int J Pharm; 2015 Aug; 491(1-2):367-74. PubMed ID: 26151107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG.
    Rastogi N; Goh KS; Berchel M; Bryskier A
    J Antimicrob Chemother; 2000 Oct; 46(4):565-70. PubMed ID: 11020253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.
    Kaushik A; Ammerman NC; Tasneen R; Story-Roller E; Dooley KE; Dorman SE; Nuermberger EL; Lamichhane G
    J Antimicrob Chemother; 2017 Aug; 72(8):2320-2325. PubMed ID: 28575382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rifapentine: its role in the treatment of tuberculosis.
    Temple ME; Nahata MC
    Ann Pharmacother; 1999 Nov; 33(11):1203-10. PubMed ID: 10573321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple combination dry powder formulation of pretomanid, moxifloxacin, and pyrazinamide for treatment of multidrug-resistant tuberculosis.
    Fan C; Eedara BB; Sinha S; Uddin MKM; Doyle C; Banu S; Das SC
    Int J Pharm; 2024 Apr; 654():123984. PubMed ID: 38461874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
    Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
    J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.